We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
15.50 | 0.98% | 1,599.00 | 1,599.50 | 1,600.50 | 1,600.00 | 1,575.00 | 1,579.50 | 5,149,016 | 16:35:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.37 | 65.87B |
PHILADELPHIA, June 24, 2015 /PRNewswire/ -- GlaxoSmithKline (LSE: GSK) announced today that the U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination, including BEXSERO® (Meningococcal Group B Vaccine), in individuals aged 16 to 23 (with a preferred age of 16-18). This recommendation means that the decision to vaccinate against meningococcal group B will be made by qualified healthcare professionals, based on individual patient risk assessment. BEXSERO® was approved by the U.S. Food and Drug Administration (FDA) in January 2015 through an accelerated approval pathway for use in individuals aged 10 through 25 years and acquired by GSK in March 2015 following the closure of the three-part transaction with Novartis.
"GSK welcomes this vote as an important step forward to help protect against meningococcal disease in the U.S.," said Patrick Desbiens, Senior Vice President, U.S. Vaccines, GSK. "Meningococcal disease is fast-moving, unpredictable and can cause irreversible damage, so vaccination is the best tool to help prevent it. Today's vote is the latest milestone on a 20-year journey to develop a vaccine in order to help protect individuals from this devastating condition."
Meningococcal disease is a rare but serious bacterial infection that can be difficult to diagnose within 24 hours of symptom onset, and can leave those affected with lifelong disability. According to the CDC, each year there are 800-1,200 cases of all serogroups of meningococcal disease across all ages, and with an approximate 12 percent mortality rate. Five serogroups of Neisseria meningitidis [A, B, C, W-135 and Y] cause the majority of cases of meningococcal disease in the U.S. Meningococcal group B is one of the most prevalent serogroups, accounting for 32 percent of all reported U.S. cases in all age groups in 2013.
During today's meeting, the ACIP also voted to include BEXSERO® in the CDC's Vaccines for Children (VFC) program for ages 16 through 18. The ACIP voted in February for the use of meningococcal group B vaccines in people greater than 10 years of age at increased risk for meningococcal group B disease and this was published on June 12, 2015. The recommendation endorsed today by the ACIP will become final upon publication in a future Morbidity and Mortality Weekly Report.
GSK is evaluating the safety and immune response of a pentavalent meningococcal vaccine (A, C, W-135, Y, plus B) which is now in Phase 2 research. GSK plans to continue to invest in vaccines against this disease as a key part of its growth strategy.
About BEXSERO®
BEXSERO® is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO® is approved for use in individuals 10 through 25 years of age. Approval of BEXSERO® is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the U.S. The effectiveness of BEXSERO® against diverse serogroup B strains has not been confirmed.
Outside of the U.S., BEXSERO® is now licensed in 36 countries including the member states of the European Union, Australia and Canada for use in individuals from 2 months of age and older.
BEXSERO® (Meningococcal Group B Vaccine) Important Safety Information
Please click here for full Prescribing Information.
GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
GSK enquiries: |
|||
US Media enquiries: |
Sarah Alspach |
+1 202 715 1048 |
(Washington, DC) |
Mary Anne Rhyne |
+1 919 483 0492 |
(North Carolina) | |
Melinda Stubbee |
+1 919 483 2510 |
(North Carolina) | |
Jenni Ligday |
+1 202 715 1049 |
(Washington, DC) | |
Karen Hagens |
+1 919 483 2863 |
(North Carolina) | |
Gwynne Oosterbaan |
+1 215 751 7468 |
(Pennsylvania) | |
Anna Padula |
+1 215 751 4271 |
(Pennsylvania) | |
Analyst/Investor enquiries: |
Ziba Shamsi |
+44 (0) 20 8047 5543 |
(London) |
Tom Curry |
+ 1 215 751 5419 |
(Philadelphia) | |
Gary Davies |
+44 (0) 20 8047 5503 |
(London) | |
James Dodwell |
+44 (0) 20 8047 2406 |
(London) | |
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/us-cdc-committee-recommends-physicians-make-individual-decisions-on-the-use-of-meningococcal-group-b-vaccines-300104263.html
SOURCE GlaxoSmithKline
Copyright 2015 PR Newswire
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions